TNM stage I pancreatic ductal adenocarcinoma patients without pathological risk may drive limited benefit from adjuvant chemotherapy
Objective In this study, we identified pathological risk factors as key determinants of whether patients with pancreatic ductal adenocarcinoma (PDAC) can benefit from adjuvant chemotherapy following radical resection. Methods This single-center retrospective study enrolled 520 patients who underwent curative-intent res...